Steward Partners Investment Advisory’s Acrivon Therapeutics ACRV Stock Holding History

Steward Partners Investment Advisory’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$453	Buy	+326	New	+$569	﹤0.01%	4270

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Partners Investment Advisory's ACRV Position: Q1 2026 in Review

Steward Partners Investment Advisory opened a new position in Acrivon Therapeutics (ACRV) in Q1 2026: 326 shares worth $453. The stake represents ﹤0.01% of the portfolio and ranks #4270 among its holdings.

44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Steward Partners Investment Advisory held 326 shares of Acrivon Therapeutics worth $453 as of Q1 2026.
Acrivon Therapeutics was a new Steward Partners Investment Advisory position in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #4270 holding.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.